E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016

E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016
Published Jun 28, 2016
64 pages — Published Jun 28, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016, provides in depth analysis on E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted pipeline therapeutics.

The report provides comprehensive information on the E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.)
- The report reviews E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
- The report assesses E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC

  
Source:
Document ID
GMDHC0143TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Overview71
Therapeutics Development84
  E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Stage of Development81
  E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Therapy Area91
  E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Indication102
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Pipeline Products Glance122
  Late Stage Products121
  Early Stage Products131
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Companies143
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Products under Development by Universities/Institutes172
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Therapeutics Assessment195
  Assessment by Monotherapy/Combination Products191
  Assessment by Mechanism of Action201
  Assessment by Route of Administration211
  Assessment by Molecule Type222
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Companies Involved in Therapeutics Development247
  Ascentage Pharma Group Corporation, Ltd.241
  Astex Pharmaceuticals, Inc.251
  Bristol-Myers Squibb Company261
  Debiopharm International SA271
  F. Hoffmann-La Roche Ltd.281
  Novartis AG291
  Takeda Pharmaceutical Company Limited301
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Drug Profiles3117
  ASTX-660 Drug Profile311
  Debio-1143 Drug Profile323
  FL-118 Drug Profile352
  LCL-161 Drug Profile372
  SM-1200 Drug Profile391
  Small Molecule 2 to Inhibit XIAP for Oncology Drug Profile401
  Small Molecule to Inhibit XIAP and c-IAP for Melanoma Drug Profile411
  Small Molecule to Inhibit XIAP for Oncology Drug Profile421
  Small Molecules to Inhibit XIAP for Oncology Drug Profile431
  Synthetic Peptides to Inhibit XIAP for Oncology Drug Profile441
  T-3256336 Drug Profile451
  xaripin D Drug Profile461
  xaripin P Drug Profile471
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Dormant Projects483
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Discontinued Products511
E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) Featured News &Press Releases5211
  Jun 07, 2016: Debiopharm International initiates clinical Phase II study evaluating Debio 1143 in Ovarian Cancer521
  Jun 02, 2016: FDA grants Orphan Drug Designation to Debiopharm International SA s IAP inhibitor Debio 1143 in the treatment of ovarian cancer521
  Dec 08, 2015: EMA grants Orphan Drug Designation to Debiopharm International s IAP inhibitor Debio 1143 in the treatment of Ovarian Cancer531
  Nov 03, 2015: Debiopharm International presents positive preliminary results from Phase 1 trials in the development of the IAP inhibitor Debio 1143 at the 27th EORTC-NCI-AACR symposium in Boston531
  Apr 28, 2015: Camptothecin Analog FL118 Can Overcome Treatment Resistance, Outperform Approved Therapies541
  Apr 16, 2015: Debiopharm International announces results of key oncology program, Debio 1143 at 2015 AACR Conference541
  Dec 15, 2014: Roswell Park Study Suggests Additional Applications for FL118 as Personalized Therapy for Cancer552
  Nov 18, 2014: Debiopharm Group Presents Advances Of key Oncology Product On Debio 1143 Clinical Program At The 26th EORTC-NCI-AACR Symposium In Barcelona571
  May 28, 2014: Debiopharm tp present data on Debio 1143 at the 50th ASCO Annual Meeting571
  Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent581
  Dec 31, 2013: Scientists Identify Key Structural Qualities that Distinguish Novel Anticancer Agent591
  Jun 04, 2013: Debiopharm Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies For Patients With Selected Solid Malignancies591
  Apr 02, 2013: Roswell Park Scientists Advance Findings about Novel, Low-Toxicity Anticancer Agent601
  Sep 20, 2012: RPCI Scientists Publish Findings About Novel Anticancer Agent611
  Mar 29, 2011: University Of Michigan Researchers Discover New Cancer Drug, AT-406612
Appendix632
  Methodology631
  Coverage631
  Secondary Research631
  Primary Research631
  Expert Panel Validation631
  Contact Us631
  Disclaimer641

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/E3-Ubiquitin-Protein-Ligase-XIAP-Baculoviral-IAP-Repeat-Containing-Protein-4-or-IAP-Like-Protein-or-X-Linked-Inhibitor-Of-Apoptosis-Protein-or-XIAP-or-EC-6-3-2-Pipeline-Review-H1-2016-2088-16045>
  
APA:
Global Markets Direct - Market Research. (2016). E3 Ubiquitin-Protein Ligase XIAP (Baculoviral IAP Repeat-Containing Protein 4 or IAP-Like Protein or X-Linked Inhibitor Of Apoptosis Protein or XIAP or EC 6.3.2.) - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/E3-Ubiquitin-Protein-Ligase-XIAP-Baculoviral-IAP-Repeat-Containing-Protein-4-or-IAP-Like-Protein-or-X-Linked-Inhibitor-Of-Apoptosis-Protein-or-XIAP-or-EC-6-3-2-Pipeline-Review-H1-2016-2088-16045>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.